Завантаження...
An adenovirus-vectored RVF vaccine confers complete protection against lethal RVFV challenge in A129 mice
Instruction: Rift valley fever virus (RVFV) is a mosquito-transmitted bunyavirus that causes severe disease in animals and humans. Nevertheless, there are no vaccines applied to prevent RVFV infection for human at present. Therefore, it is necessary to develop a safe and effective RVFV vaccine. Meth...
Автори: | , , , , , , , , , |
---|---|
Формат: | Online Стаття Текст |
Мова: | English |
Опубліковано: |
Frontiers Media S.A.
2023
|
Предмети: | |
Онлайн доступ: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011166/ https://www.ncbi.nlm.nih.gov/pubmed/36925463 http://dx.doi.org/10.3389/fmicb.2023.1114226 |
Резюме: | Instruction: Rift valley fever virus (RVFV) is a mosquito-transmitted bunyavirus that causes severe disease in animals and humans. Nevertheless, there are no vaccines applied to prevent RVFV infection for human at present. Therefore, it is necessary to develop a safe and effective RVFV vaccine. Methods: We generated Ad5-GnGcopt, a replication-deficient recombinant Ad5 vector (human adenovirus serotype 5) expressing codon-optimized RVFV glycoproteins Gn and Gc, and evaluated its immunogenicity and protective efficacy in mice. Results and Discussion: Intramuscular immunization of Ad5-GnGcopt in mice induces strong and durable antibody production and robust cellular immune responses. Additionally, a single vaccination with Ad5-GnGcopt vaccination can completely protect interferon-α/β receptor-deficient A129 mice from lethal RVFV infection. Our work indicates that Ad5-GnGcopt might represent a potential vaccine candidate against RVFV. However, further research is needed, first to confirm its efficacy in a natural animal host, and ultimately escalate as a potential vaccine candidate for humans. |
---|